Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?
Unresectable pancreatic cancers have an extremely dismal prognosis and chemoresistant nature. The treatment of pancreatic cancer is still problematic. Gemcitabine is a promising new agent that has been studied recently for palliation of advanced pancreatic cancer. However, the response rates have been highly variable, and are often irreproducible. To improve this low response rate, various treatments are needed because no standard treatment exists. Intra-arterial chemotherapy is considered to take advantage of the first pass effect of the drug, generating higher local drug concentrations in tumor cells with lower toxicity. Regional intra-arterial chemotherapy may provide high levels of cytostatic concentrations within the tumor and, simultaneously, a low rate of systemic side effects compared with systemic administration of anti-neoplastic drugs. Intra-arterial chemotherapy has been introduced as an alternative treatment for advanced pancreatic cancer. Further clinical trials of this method should be subjected to a prospective randomized controlled study for advanced pancreatic cancer.
Ishikawa
Toru
T
Department of Gastroenterology, Saiseikai Niigata Second Hospital, Teraji 280-7, Niigata 950-1104, Japan. toruishi@ngt.saiseikai.or.jp
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D012039:Regional Blood Flow / Q000187:drug effects
D000970:Antineoplastic Agents
Br J Surg. 1994 Jan;81(1):102-7
7906180
Ann Surg. 1987 Sep;206(3):366-73
2820322
Ann Oncol. 1995 Oct;6(8):801-4
8589018
Lancet Oncol. 2005 Sep;6(9):644
16161265
Gan To Kagaku Ryoho. 2004 Oct;31(10):1555-8
15508450
Ann Oncol. 2000 May;11(5):569-73
10907950
Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5
1987845
Gan To Kagaku Ryoho. 2003 Aug;30(8):1151-5
12938272
Hepatogastroenterology. 2007 Dec;54(80):2378-82
18265669
Biorheology. 1984;21(4):503-8
6487762
Cancer. 1981 Mar 15;47(6 Suppl):1724-8
6456058
J Natl Cancer Inst. 1989 Jan 18;81(2):116-24
2562856
In Vivo. 2006 Nov-Dec;20(6A):751-5
17203761
Pancreatology. 2003;3(5):367-73; discussion 373-4
14526145
Cancer. 1996 Aug 1;78(3 Suppl):633-8
8681302
Eur J Cancer. 1996 Jun;32A(6):1039-50
8763346
Am J Clin Oncol. 1982 Oct;5(5):555-8
6217742
Gan To Kagaku Ryoho. 2001 Aug;28(8):1137-40
11525032
Gan To Kagaku Ryoho. 2001 Apr;28(4):521-5
11329788
Eur J Cancer. 1978 Jul;14(7):761-4
658101
Hepatogastroenterology. 1993 Oct;40(5):433-42
8270232
Int J Pancreatol. 1998 Jun;23 (3):181-6
9629517
Am J Surg. 1994 Oct;168(4):361-4
7943597
Gan To Kagaku Ryoho. 2005 Apr;32(4):523-7
15853221
Hepatogastroenterology. 1998 May-Jun;45(21):644-50
9684110
Cancer. 1996 Aug 1;78(3 Suppl):664-73
8681305
N Engl J Med. 1993 May 20;328(20):1485-6
8479469
Cancer Treat Rev. 1975 Sep;2(3):193-214
1104163
Hepatogastroenterology. 1998 May-Jun;45(21):638-43
9684109
Gan To Kagaku Ryoho. 2005 Apr;32(4):469-72
15853212
J Hepatobiliary Pancreat Surg. 2002;9(1):61-75
12021899
Cancer. 1985 Jan 15;55(2):311-6
2981143
Cancer. 1981 Jan 1;47(1):207-14
7459811
Med Klin (Munich). 1995 Sep 15;90(9):501-5
7476726
World J Gastroenterol. 2007 Jun 14;13(22):3080-3
17589923
Clin Exp Metastasis. 1997 Sep;15(5):484-98
9247251
World J Surg. 1999 Sep;23(9):946-9
10449825
Cancer. 2000 Jul 15;89(2):303-13
10918160
J Clin Oncol. 1992 Jul;10(7):1112-8
1296590
Br J Cancer. 1996 May;73(10):1260-4
8630289
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
Hematol Oncol Clin North Am. 2002 Feb;16(1):199-215
12063827
Ann Oncol. 1996 Apr;7(4):347-53
8805925